New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2013
10:15 EDTAEO, TUP, HMY, CRH, VELT, POT, CHK, SNY, DKS, MOS, AGU, GHLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Agrium (AGU) downgraded to Neutral from Overweight at HSBC... Chesapeake (CHK) downgraded to Neutral from Positive at Susquehanna... Harmony Gold (HMY) downgraded to Sell from Neutral at UBS... Mosaic (MOS) downgraded to Underweight from Neutral at HSBC... Potash (POT) downgraded to Underweight from Overweight at HSBC... Tupperware Brands (TUP) downgraded to Market Perform from Outperform at BMO Capital... Dick's Sporting (DKS) downgraded to In-Line from Outperform at Imperial Capital... Velti (VELT) downgraded at RBC Capital... American Eagle (AEO) downgraded to Neutral from Overweight at Piper Jaffray... Sanofi (SNY) downgraded to Market Perform from Outperform at Cowen... CRH Plc. (CRH) downgraded to Outperform from Strong Buy at Raymond James... Greenhill & Co. (GHL) downgraded to Market Perform from Outperform at JMP Securities.
News For AGU;CHK;HMY;MOS;POT;TUP;DKS;VELT;AEO;SNY;CRH;GHL From The Last 14 Days
Check below for free stories on AGU;CHK;HMY;MOS;POT;TUP;DKS;VELT;AEO;SNY;CRH;GHL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 23, 2014
06:16 EDTSNYPharmaceutical companies narrowing focus, WSJ reports
Subscribe for More Information
April 21, 2014
11:33 EDTSNYAward of $16M to Sanofi, Abbott for damages upheld on appeal
The Court of Appeals for the Federal Circuit affirmed a lower court ruling that Glenmark Pharmaceuticals infringed a patent related to the antihypertension drug Tarka that is owned by or exclusively licensed to Sanofi (SNY), Abbott Labs (ABT), and their related companies. In the prior case, Glenmark admitted infringement and the jury awarded $15.2M in lost profits and about $800K in price erosion damages. The appeals court affirmed the district court's jurisdiction in the matter, as well as its judgment and related rulings. Reference Link
08:36 EDTSNYAastrom announces definitive agreement to acquire Sanofi's CTRM business
Aastrom Biosciences (ASTM) announced that it has entered into a definitive agreement to acquire Sanofi's (SNY) Cell Therapy and Regenerative Medicine, or CTRM, business for a purchase price of $6.5M, with $4M payable in cash at closing and $2.5M payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Through the CTRM acquisition, Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. Aastrom will also acquire global manufacturing and production centers located in the United States and Denmark.
08:32 EDTSNYAastrom announces definitive agreement to acquire Sanofi's CTRM business
08:16 EDTAGU, POTPossible short-term trading opportunity for fertilizers, says Cowen
Cowen believes a short term trading opportunity may exist for the fertilizer shares heading into the Spring application season. The firm favors the Phosphate, Nitrogen, and Potash nutrients in that order based on supply/demand and grain outlook. Cowen remains cautious on the group longer term due to fundamentals and a lack of any catalysts. They have changed their downside risk limits but have not upgraded any shares.
07:21 EDTSNYFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 16, 2014
09:15 EDTSNYImpax launches generic Renvela for kidney disease licensed from Sanofi
Impax Laboratories (IPXL) is commencing shipment of authorized generic Renvela 800 mg tablets, through Global Pharmaceuticals, Impax's generics division. Renvela is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Under the terms of a settlement agreement, Sanofi (SNY) company Genzyme agreed to grant Impax a license to sell an allotment of a specified number of bottles of an authorized generic version of Renvela tablets commencing on April 16. Impax continues to pursue approval of its pending Abbreviated New Drug Application for generic Renvela with the FDA.
05:35 EDTGHLGreenhill & Co. upgraded to Neutral from Reduce at Nomura
Subscribe for More Information
April 15, 2014
16:22 EDTMOSOn The Fly: Closing Wrap
Subscribe for More Information
13:19 EDTMOSArcher Daniels announces $350M unit sale to Mosaic, other actions
Archer Daniels Midland (ADM) announced three actions in the company’s ongoing portfolio management. ADM has signed an agreement to sell its fertilizer business in Brazil and Paraguay to The Mosaic Company (MOS) for $350M. The transaction consists primarily of five ADM-owned blending facilities in Brazil and Paraguay. The purchase price includes $150M in working capital. As part of the transaction, ADM will purchase fertilizer from Mosaic after the closing and will continue to supply certain fertilizer customers in Brazil and Paraguay. ADM also announced it will pursue the sale of its chocolate business, while retaining the majority of its cocoa press operations. The company has engaged advisers to facilitate the sale process. Finally, ADM announced it will acquire the remaining 20% minority stake of Alfred C. Toepfer International for EUR83M, representing about 1.1x net book value. The proposed transaction, which is occurring through the exercise of a put agreement by Union InVivo, will be subject to customary regulatory approvals. Since 2002, ADM has owned 80% of Toepfer. InVivo will remain a strategic business partner for ADM in Europe.
12:56 EDTAGUAgrium files U.S. $2.5B mixed securities shelf
Subscribe for More Information
12:31 EDTMOSMosaic to acquire Archer Daniels' Brazil, Paraguay fertilizer units
Mosaic (MOS) signed definitive agreements with Archer Daniels Midland (ADM) to acquire its fertilizer distribution business in Brazil and Paraguay for $350M. The purchase price assumes the delivery of $150M in working capital at closing. This acquisition is expected to accelerate Mosaic's previously announced growth plans in Brazil as well as replace planned internal investments in that country. Under the terms of the agreement, Mosaic would acquire four blending and warehousing facilities in Brazil, one in Paraguay and additional warehousing and logistics service capabilities. The acquisition of ADM's fertilizer distribution business would increase Mosaic's annual distribution in the region from approximately 4M metric tonnes to about 6M metric tonnes of crop nutrients. The parties have also negotiated the terms of five-year fertilizer supply agreements providing for Mosaic to supply ADM's fertilizer needs in Brazil and Paraguay. Mosaic will fund the acquisition with cash from operations. The transaction is not expected to impact Mosaic's shareholder distribution plans. The proposed sale will be contingent on customary regulatory approvals.
11:44 EDTPOTPotash Corp. advances after report says BHP could make new bid
Subscribe for More Information
10:09 EDTPOTPotash upgraded to Neutral from Sell at Miller Tabak
Subscribe for More Information
09:16 EDTPOTOn The Fly: Pre-market Movers
Subscribe for More Information
09:07 EDTPOTPotash volatility expected to move on speculation of being target
Subscribe for More Information
07:46 EDTPOTPotash Corp. speculated to be targeted again by BHP Billiton, Globe & Mail says
Subscribe for More Information
06:32 EDTSNYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 11, 2014
13:36 EDTAEOGap falls after experiencing sharp decline in March SSS
Subscribe for More Information
07:06 EDTSNYVIVUS announces avanafil clinical data presentation
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use